EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis

Tyler Robinson iD, June Escara-Wilke, Jinlu Dai, Johann Zimmermann, Evan T Keller iD

The Prostate · 2023

DOI: 10.1002/pros.24584 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Tyler Robinson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate cancer (PCa) bone metastases have been shown to be more resistant to docetaxel than soft tissue metastases. The proinflammatory chemokine receptor CXCR4 has been shown to confer resistance to docetaxel (DOC) in PCa cells. Balixafortide (BLX) is a protein epitope mimetic inhibitor of CXCR4. Accordingly, we hypothesized that BLX would enhance DOC‐mediated antitumor activity in PCa bone metastases.

Methods

PC‐3 luciferase‐labeled cells were injected into the tibia of mice to model bone metastases. Four treatment groups were created: vehicle, DOC (5 mg/kg), BLX (20 mg/kg), and combo (receiving both DOC and BLX). Mice were injected twice daily subcutaneously with either vehicle or BLX starting on Day 1 and weekly intraperitoneally with DOC starting on Day 1. Tumor burden was measured weekly via bioluminescent imaging. At end of study (29 days), radiographs were taken of the tibiae and blood was collected. Serum levels of TRAcP, IL‐2, and IFNγ levels were measured using ELISA. Harvested tibiae were decalcified and stained for Ki67, cleaved caspase‐3, and CD34 positive cells or microvessels were quantified.

Results

Tumor burden was lower in the combo group compared to the DOC alone group. Treatment with the combination had no impact on the number of mice with osteolytic lesions, however the area of osteolytic lesions was lower in the combo group compared to the vehicle and BLX groups, but not the DOC group. Serum TRAcP levels were lower in the combo compared to vehicle group, but not the other groups. No significant difference in Ki67 staining was found among the groups; whereas, cleaved caspase‐3 staining was lowest in the Combo group and highest in the BLX group. The DOC and combo groups had more CD34+ microvessels than the control and BLX groups. There was no difference between the treatment groups for IL‐2, but the combo group had increased levels of IFNγ compared to the DOC group.

Conclusions

Our data demonstrate that a combination of BAL and DOC has greater antitumor activity in a model of PCa bone metastases than either drug alone. These data support further evaluation of this combination in metastatic PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBone NeoplasmsHumansMaleAnimalsMiceDocetaxelCaspase 3Disease Models, AnimalInterleukin-2Ki-67 AntigenTartrate-Resistant Acid PhosphataseCell Line, TumorReceptors, CXCR4Peptides, Cyclic

Stichwörter der Autor:innen

CXCL12adjuvant therapyinterferonosteolysisskeletontaxol

Substanzen

DocetaxelCaspase 3Interleukin-2Ki-67 AntigenTartrate-Resistant Acid PhosphataseReceptors, CXCR4balixafortidePeptides, CyclicCXCR4 protein, human

Autor:innen und Institutionen

  • Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
  • Spexis AG, Allschwil, Switzerland.
  • Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan, USA.
  • Single Cell Spatial Analysis Program, University of Michigan, Ann Arbor, Michigan, USA.

ORCID-Profile: Tyler Robinson, Evan T Keller

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Robinson, T., Escara-Wilke, J., Dai, J., Zimmermann, J., & Keller, E. T. (2023). A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis. The Prostate. https://doi.org/10.1002/pros.24584

Vancouver

Robinson T, Escara-Wilke J, Dai J, Zimmermann J, Keller ET. A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis. The Prostate. 2023. doi:10.1002/pros.24584

BibTeX
@article{Robinson2023,
  author = {Robinson, Tyler and Escara-Wilke, June and Dai, Jinlu and Zimmermann, Johann and Keller, Evan T},
  title = {A CXCR4 inhibitor (balixafortide) enhances docetaxel‐mediated antitumor activity in a murine model of prostate cancer bone metastasis},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24584}
}
Kostenlos starten →